Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...

Buzz on the bullboards: Geopolitics are back in the driver’s seat

Get “Buzz on the Bullboards” delivered to your inbox every third Thursday! Buzz on the Bullboards | Sign Up Here That macro ...
Pharmabiz

Natera submits premarket approval to US FDA for Signatera CDx for detection of MRD in patients with muscle-invasive bladder cancer

Natera submits premarket approval to US FDA for Signatera CDx for detection of MRD in patients with muscle-invasive bladder cancer: Austin, Texas Wednesday, February 4, 2026, 18:0 ...

Natera Submits Signatera™ CDx PMA to FDA

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the submission of its premarket approval (PMA) to the U.S. Food and Drug Administration (FDA) for ...

Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight's Oncolytic Virus Competitive Landscape 2026 report provides comprehensive global coverage of pipeline oncolytic ...
Le Lézard

Natera Submits Signateratm CDx PMA to FDA

Natera, Inc. , a global leader in cell-free DNA and precision medicine, today announced the submission of its premarket approval (PMA) to the U.S. Food and Drug Administration (FDA) for Signateratm ...

DelveInsight Business Research, LLP: Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

The oncolytic virus therapy landscape has expanded steadily over the past decade, with over 100 companies worldwide pursuing clinical or preclinical programs. A few leaders, such as Candel Therapeutic ...